Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0001193125-26-122272

Chief Executive Officer sold 10,020 shares at $46.78 ($468,736)

  • Chief Executive Officer acquired 19,687 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Kulkarni Samarth · Chief Executive Officer

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2026-03-20 Exercise or conversion : show line 1 in the form +19,687 265,521 D
2026-03-23 Sale : show line 2 in the form −10,020 $46.78 $468,736 255,501 D
Open-market sales · 10,020 sh · avg $46.78 · $468,736

Table II: Derivative

3 lines
Date Transaction Shares Owned after D/I
2026-03-20 Grant or award : show line 3 in the form Stock Option (Right to Buy) +114,249 114,249 D
2026-03-20 Grant or award : show line 4 in the form Restricted Stock Units +81,875 81,875 D
2026-03-20 Exercise or conversion : show line 5 in the form Restricted Stock Units −19,687 39,375 D
Loading xslF345X06/ownership.xml…